News · 26 weeks55-55%
2026-03-012026-08-23
Mix2490d
- Insider11(46%)
- Other5(21%)
- SEC Filings5(21%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- PRAtriCure to Participate in the 2026 Wells Fargo Health Care ConferenceAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure’s management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company’s website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Af
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.SCHEDULE 13G/A - AtriCure, Inc. (0001323885) (Subject)
- INSIDERDirector Prange Karen sold $138,283 worth of shares (3,564 units at $38.80), decreasing direct ownership by 14% to 22,809 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector Yuen Maggie sold $134,470 worth of shares (3,500 units at $38.42), decreasing direct ownership by 20% to 14,015 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERPresident, CEO, & Director Carrel Michael H gifted 4,700 shares, decreasing direct ownership by 0.60% to 774,434 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Scientific Officer Doraiswamy Vinayak sold $233,280 worth of shares (6,000 units at $38.88), decreasing direct ownership by 6% to 86,511 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector Wehrwein Sven exercised 25,000 shares at a strike of $19.95 and sold $946,000 worth of shares (25,000 units at $37.84) (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Mktg & Strategy Officer Noznesky Justin J sold $239,862 worth of shares (6,182 units at $38.80), decreasing direct ownership by 6% to 100,219 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- SECSEC Form 144 filed by AtriCure Inc.144 - AtriCure, Inc. (0001323885) (Subject)
- SECSEC Form S-8 filed by AtriCure Inc.S-8 - AtriCure, Inc. (0001323885) (Filer)
- SECSEC Form S-8 filed by AtriCure Inc.S-8 - AtriCure, Inc. (0001323885) (Filer)
- SECSEC Form 10-Q filed by AtriCure Inc.10-Q - AtriCure, Inc. (0001323885) (Filer)
- PRInspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of DirectorsMINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of seasoned medical device executive Michael H. Carrel to its Board of Directors effective July 20. "We are pleased to welcome Mr. Carrel to our Board of Directors," said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. "Mike brings extensive executive leadership, board and medical device experience, including a strong track record of developing and commercializing minimally invasive therapies, and we look forwar
- PRAtriCure to Participate at Upcoming Investor ConferencesAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCure’s management is scheduled to participate in meetings at the 11th Annual Needham Virtual MedTech & Diagnostics Conference on Monday, August 10, 2026. AtriCure will also attend the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026. Management will participate in a fireside chat at 11:30 a.m. Eastern Standard Time and interested parties may access a live audio webcast by visitin
- SECAtriCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AtriCure, Inc. (0001323885) (Filer)
- PRAtriCure Reports Second Quarter 2026 Financial ResultsSecond Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million Second Quarter 2026 cash generation of $21.6 million AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. "Our team delivered healthy growth and a significant step up in profitability in the second quarter," said Michael Carrel, President and Chief Executive Officer. "Our innovative tec
- INSIDERPresident, CEO, & Director Carrel Michael H was granted 636 shares, increasing direct ownership by 0.08% to 779,134 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Scientific Officer Doraiswamy Vinayak was granted 636 shares, increasing direct ownership by 0.69% to 92,511 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Legal Officer Dahlquist Karl S. was granted 636 shares, increasing direct ownership by 0.66% to 96,689 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Operating Officer Seith Douglas J was granted 527 shares, increasing direct ownership by 0.23% to 229,867 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Technical Officer Privitera Salvatore was granted 636 shares, increasing direct ownership by 0.40% to 158,684 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- PRAtriCure to Announce Second Quarter 2026 Financial ResultsAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss its second quarter financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir
- SECSEC Form SD filed by AtriCure Inc.SD - AtriCure, Inc. (0001323885) (Filer)
- PRAtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care ConferenceAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related c
- INSIDERDirector Prange Karen sold $85,950 worth of shares (3,000 units at $28.65), decreasing direct ownership by 10% to 26,373 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
ATRC FAQ
7 questionsWhat does AtriCure Inc. do?
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation...Where does ATRC stock trade?
AtriCure Inc. (ATRC) is listed on NASDAQ.What sector and industry is ATRC in?
AtriCure Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did AtriCure Inc. go public?
AtriCure Inc. (ATRC) completed its IPO in 2005.What are analysts saying about ATRC?
AtriCure Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2026-02-18. Recent price targets range from $3200.00 to $4000.00.What companies are similar to ATRC?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare ATRC side-by-side with any of them on Quantisnow.How can I track ATRC on Quantisnow?
Quantisnow aggregates AtriCure Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATRC to receive live email and push alerts on every new disclosure.